Dry Eye
Conditions
Brief summary
This aim of this study to quantify the subjective ocular awareness of different eyelid cleansing wipes available for the management of Demodex folliculorum.
Interventions
DRUGSensitive Eyes® Plus Saline Solution
Sensitive Eyes® Plus Saline Solution
OTHEROust™ Demodex® Wipes™
Oust™ Demodex® Wipes™
OTHERI-LID N LASH PLUS® Eyelid Cleanser
I-LID N LASH PLUS® Eyelid Cleanser
OTHERBlephadex Lid Wipes
Blephadex Lid Wipes
OTHEREye Cleanse Lid Wipes
Eye Cleanse Lid Wipes
OTHERBlephademodex
Blephademodex
Sponsors
University of Waterloo
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Each participant receives 6 different interventions in random order
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Is between the ages of 18 to 60 and has the full legal capacity to volunteer; 2. Has read and signed an informed consent letter; 3. Agrees to refrain from the use of ocular lubricants during the study period; 4. Agrees to not to use eye-related cosmetics for upcoming study visits 5. Is willing to use the study products 6. Is willing and able to follow instructions regarding study procedures and maintain the appointment schedule; 7. Has corneal sensitivity within physiological limits.
Exclusion criteria
1. Is participating in any concurrent clinical or research study; 2. Is a contact lens wearer (due to reduced corneal sensitivity); 3. Has any known active\* ocular disease and/or infection; including moderate and severe dry eye (OSDI ≥ 23); 4. Has a systemic (such as diabetes, thyroid disease, rheumatoid arthritis) or ocular condition (such as glaucoma) that in the opinion of the investigator may affect a study outcome variable; 5. Is using any systemic or topical medications (such as glaucoma drops, antibiotics, anti-inflammatory) that in the opinion of the investigator may affect a study outcome variable; 6. Has known sensitivity to the diagnostic pharmaceuticals to be used in the study (such as fluorescein dye to highlight structures of the eye and used regularly in optometric practice) and study products in this study; 7. Is pregnant, lactating or planning a pregnancy at the time of enrolment; (due to the possibility of fluctuating vision as a consequence of variation in hormone levels);8 8. Has undergone refractive error surgery (e.g. LASIK, PRK); 9. Is a smoker (as smoking reduces tear film stability) \* For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye (Ocular Surface Disease Index, OSDI\<23/100) are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Participant's Subjective discomfort - 120 seconds after application | 120 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - Baseline | Baseline | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 0 seconds after application | Immediately after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 15 seconds after application | 15 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 30 seconds after application | 30 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 45 seconds after application | 45 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 60 seconds after application | 60 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 75 seconds after application | 75 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 90 seconds after application | 90 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 105 seconds after application | 105 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 135 seconds after application | 135 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 150 seconds after application | 150 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 165 seconds after application | 165 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 180 seconds after application | 180 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 195 seconds after application | 195 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 210 seconds after application | 210 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 225 seconds after application | 225 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 240 seconds after application | 240 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 255 seconds after application | 255 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 270 seconds after application | 270 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 285 seconds after application | 285 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 300 seconds after application | 300 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 330 seconds after application | 330 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 360 seconds after application | 360 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 390 seconds after application | 390 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 420 seconds after application | 420 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 450 seconds after application | 450 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 480 seconds after application | 480 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 510 seconds after application | 510 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 540 seconds after application | 540 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 570 seconds after application | 570 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Participant's Subjective discomfort - 600 seconds after application | 600 seconds after application | Rate the intensity of participant's ocular discomfort (0 is no discomfort, 10 is maximal discomfort) |
| Time to comfortably open the eyes after the application of eyelid cleansing wipe | Between 0 and 600 seconds after application | Time to comfortably open the eyes after the application of eyelid cleansing wipe in seconds |
Countries
Canada
Outcome results
None listed